Palenie marihuany a ryzyko ponownej hospitalizacji psychiatrycznej chorych na schizofrenię
Słowa kluczowe:
schizofrenia, marihuana, hospitalizacjaAbstrakt
Marihuana jest najczęściej stosowanym narkotykiem przez osoby chore na schizofrenię, a jej spożycie w tej populacji jest wyższe w porównaniu do populacji ogólnej. Schizofrenia jest przewlekłą chorobą psychiczną charakteryzującą się wysokim prawdopodobieństwem nawrotu i rehospitalizacji. Jednym z kierunków badań poszukujących związków pomiędzy paleniem marihuany a schizofrenią jest zagadnienie wpływu używania konopi na ryzyko ponownej hospitalizacji psychiatrycznej. W poniższej pracy dokonano przeglądu dostępnego piśmiennictwa mającego związek z tematem wpływu palenia marihuany u osób chorych na schizofrenię na ryzyko rehospitalizacji. Dotychczas przeprowadzone badania wskazują, że palenie marihuany może stanowić istotny czynnik ryzyka nawrotu schizofrenii. Ustalenie dokładnego mechanizmu wpływu palenia marihuany na ryzyko hospitalizacji napotyka na trudności, z uwagi na złożoność powiązań pomiędzy używaniem konopi a psychozą.
Badania oceniające związek palenia marihuany z nasileniem objawów schizofrenii dają niespójne wyniki. Podkreśla się natomiast, że palenie marihuany ma związek z niższym wiekiem zachorowania na schizofrenię i gorszą współpracą pacjentów w zakresie leczenia, co może skutkować większym ryzykiem nawrotu i rehospitalizacji. Dotychczasowe badania wskazują, że palenie marihuany może mieć istotny wpływ na przebieg i rokowanie w schizofrenii, co powinno skłaniać do dalszych badań.
Bibliografia
1. Peters H., Nahas GG.:A brief history of four millennia (B.C. 2000 - A.D. 1974). W: Marihuana and medicine, red.: Nahas GG., Sutin KM., Harvey D, S. Agurell S. Humana Press, Totowa, NJ 1999; 3-7.
2. Trezza V., Cuomo V., Vanderschuren LJ. Cannabis and developing brain: insight from behavior. Eur J Pharmacol. 2008; 585(2-3): 441-452.
3. Fried PA., Smith AM. A literature review of the consequences of prenatal marihuana exposure. An emerging theme of a deficiency in aspects of executive function. Neurotoxicol Teratol.2001; 23(1):1-11.
4. Di Forti M., Morrison P.D., Butt A., Murray RM. Cannabis use and psychiatric and cogitive disorders: the chicken or the egg? Curr. Opin. Psychiatry. 2007; 20(3): 228-234.
5. Swartz MS., Wagner HR., Swanson JW., Stroup TS., McEvoy JP., Reimherr F., Miller DD., McGee M., Khan A., Canive JM., Davis SM., Hsiao JK., Lieberman JA. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. Schizophr. Res. 2008; 100(1-3): 39-52.
6. Koskinen J., Lohonen J., Koponen H., Isohanni M., Miettunen J J.: Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophrenia Bulletin 2010; 36(6): 1115-1130.
7. Barnett JH., Werners U., Secher SM., Hill KE., Brazil R., Masson K., Pernet DE., Kirkbride JB., Murray GK., Bullmore ET., Jones PB. Substance use in a population-based clinic sample of people with first-episode psychosis. Br. J. Psychiatry. 2007; 190: 515-520.
8. Harrison I., Joyce EM., Mutsatsa SH., Hutton SB., Huddy V., Kapasi M., Barnes TR.: Naturalistic follow-up of co-morbid substance use in schizophrenia: the West London firstepisode study. Psychol. Med. 2008; 38(1): 79-88.
9. Hall WD. Cannabis use and psychosis. Drug Alcohol Rev. 1998;17:433-444.
10. Hall W., Degenhardt L., Teesson M M.:Cannabis use and psychotic disorders: an update. Drug and Alcohol Review. 2004; 23(4): 433-443.
11. Gelder MG., Lopez-Ibor JJ., Andreasen NC. New Oxford Textbook of psychiatry. Oxford: Oxford University Press. 2000: 567-621.
12. SuzukiY., Yasumura S., Fukao S., Otani K. Associated factors of rahospitalization among schizophrenic patients. Psychiatry Clin Neurosci. 2003; 57(6) :555-561.
13. San L., Bernardo M., Gomez A., Pena M.: Factors associated with relapse in patients with schizophrenia. International Journal of Psychiatry in Clinical Practice, 2013; 17(1): 2-9.
14. Addington J., Duchak V.: Reasons for substance use in schizophrenia. Acta Psychiatr. Scand. 1997; 96(5): 329-333.
15. Fowler IL., Carr VJ., Carter NT., Lewin TJ.: Patterns of current and lifetime substance use in schizophrenia. Schizophr. Bull. 1998; 24: 443-445.
16. Goswami S., Mattoo SK., Basu D., Singh, G.: Substanceabusing schizophrenics: do they self-medicate? Am. J. Addict. 2004; 13(2): 139-150.
17. Green B., Kavanagh DJ., Young RM.: Reasons for cannabis use in men with or without psychosis. Drug. Alcohol. Rev. 2004; 23(4): 445-453.
18. Schaub M., Fanghaenel K., Stohler R. Reasons for cannabis use: patients with schizophrenia versus matched healthy controls. Aust. N. Z. J. Psychiatry. 2008; 42(12): 1060-1065.
19. Schofield D., Tennant C., Nash L., Degenhardt L., Cornish A., Hobbs C., Brennan G. Reasons for cannabis use in psychosis. Aust. N. Z. J. Psychiatry. 2006; 40(6-7): 570-574.
20. Pertwee RG..: Pharmacological actions of cannabinoids. Handb Exp Pharmacol. 2005; 168:1-51.
21. Pijlman FT., Rigter SM., Hoek J., Goldschmidt HM., Niesink RJ. Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops. Addict Biol. 2005; 10(2):171-180.
22. Maldando R., Berrendero F., Ozaita A., Robledo P.: Neurochemical basis of cannabis addiction. Neuroscience. 2011; 181: 1-17.
23. Matsuda LA., Lolait SJ., Brownstein MJ., Young AC., Bonner TI.: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990; 346 (6284):561-564.
24. Munro S., Thomas KL., Abu-Shaar M.: Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993; 365(6441):61-65.
25. Glass M., Dragunow M., Faull RL.: Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience. 1997; 77(2): 299-318.
26. Herkenham M., Lynn AB., Johnson MR., Melvin LS., De Costa BR., Rice KC.: Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA. 1990; 87(5): 1932-1936.
27. Marsicano G., Lutz B.: Neromodulatory functions of the endocannabinoid system. J. Endocrinol. Invest. 2006; 29 (3 Suppl.): 27-46.
28. Pagotto U., Marsicano G., Cota D., Lutz B., Pasquali R.: The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr. Rev. 2006; 27(1): Palenie marihuany a ryzyko ponownej hospitalizacji psychiatrycznej Curr Probl Psychiatry 2013; 14(1): 29-37 35 73-100.
29. Tsou K., Brown S., Sanudo-Pena MC., Mackie K., Walker JM.: Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 1998; 83(2): 393-411.
30. Maccarrone M., Falciglia K., Di Rienzo M., Finazzi-Agro A.:Endocannabinoids, hormone-cytokine networks and human fertility. Prostaglandins Leukot. Essent. Fatty Acids. 2002; 66(2-3): 309-317.
31. Cota D., Marsicano G., Tschop M., Grubler Y., Flachskamm C., Schubert M., Auer D., Yassouridis A., Thone-Reineke C., Ortmann S., Tomassoni F., Cervino C., Nisoli E., Linthorst AC., Pasquali R., Lutz B., Stalla GK., Pagotto U.: The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest., 2003; 112(3): 423-431.
32. Cota D., Marsicano G., Vicennati V., Stalla GK., Pasquali R., Pagotto U.: Endogenous cannabinoid system as a modulator of food intake. Int. J. Obes. Relat. Metab. Disord. 2003; 27(3): 289-301.
33. Horvath T.: Endocannabinoids and the regulation of body fat: the smoke is clearing. J. Clin. Invest., 2003; 112(3): 323-326.
34. Matias I., Di Marzo V.: Endocannabinoid synthesis and degradation, and their regulation in the framework of energy balance. J. Endocrinol. Invest., 2006; 29 (3 Suppl.): 15-26.
35. Komorowski J., Stępień H. Rola układu endokannabinoidowego w regulacji czynności dokrewnej i kontroli równowagi energetycznej człowieka. Postępy Hig Med Dosw. (online).2007; 61:99-105.
36. Patel S, Roelke CT, Rademacher DJ, Cullinan WE, Hillard CJ: Endocannabinoid signaling negatively modulates stressinduced activation of the hypothalamic-pituitary-adrenal axis. Endocrinolog. 2004; 145(12): 5431-5438.
37. Pagotto U., Marsicano G., Fezza F., Theodoropoulou M., Grubler Y., Stalla J., Arzberger T., Milone A., Losa M., Di Marzo V., Lutz B., Stalla GK.: Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. J. Clin. Endocrinol. Metab. 2001; 86(6): 2687-2696.
38. Murphy LL., Newton SC., Dhali J., Chavez D.: Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level Pharmacol. Biochem. Behav. 1991; 40: 603-607.
39. Hughes CL., Everett JW., Tyrey L.: A9 - tetrahydrocannabinol suppression of prolactin secretion in the rat: lack of direct pituitary effect. Endocrinology,. 1981; 109: 876-880.
40. Benowitz NL., Jones RT, Lerner CB.: Depression of growth hormone and cortisol response to insulin-induced hypoglycemia after prolonged oral Δ9 - tetrahydrocannabinol administration in man. J. Clin. Endocrinol. Metab. 1976; 42: 938-941.
41. Lawston J., Borella A., Robinson JK., Whitaker-Azmitia PM. Changes in hippocampal morphology following chronic treatment with the synthetic cannabinoid WIN 55,212-2. Brain Research. 2000; 877(2): 407-10.
42. Chan GCK., Hinds TR., Impey S., Storm DR. Hippocampal neurotoxicity of Delta(9) tetrahydrocannabinol. Journal of Neuroscience. 1998; 18(14): 5322-32.
43. Bossong MG., Niesink RJ. Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis induced schizophrenia. Progress in Neurobiology. 2010; 92(3): 370-85.
44. Szeszko PR., Robinson DG., Sevy S., Kumra S., Rupp Cl., Betensky JD., Lencz T., Ashtari M., Kane JM., Malhorta AK., Gunduz-Bruce H, Napolitano B, Bilder RM. Anterior cingulate greymatte deficits and cannabis use in firstepisode schizophrenia. British Journal of Psychiatry 2007; 190: 230-236.
45. Bangalore SS., Prasad KMR., Montrose DM., Goradia DD., Diwadkar VA., Keshavan MS. Cannabis use and brain structural alterations in first episode schizophrenia — A region of interest, voxel based morphometric study. Schizophrenia Research 2008; 99(1-3): 1-6.
46. Solowij N., Yucel M., Respondek C., Whittle S., Lidsay E., Pantelis C., Lubman DI. Cerebellar white-matter changes in cannabis users with and without schizophrenia. Psychological Medicine 2011; 41(41): 2349-59.
47. Cohen M., Rasser PE., Peck G., Carr VJ., Ward PB., Thompson PM., Johnston P., Baker A., Schall U. Cerebellar grey-matter deficits, cannabis use and first-episode schizophrenia in adolescents and young adults. The International Journal of Neuropsychopharmacology. 2011; 4: 1-11.
48. Cahn W., Hulshoff Pol HE., Caspers E., van Haren NEM., Schnack HG., Kahn RS. Cannabis and brain morphology in recent-onset schizophrenia. Schizophrenia Research. 2004; 67(2-3): 305-7.
49. Rais M., Cahn W., Van Haren N., Schank H., Caspers E., Hulshoff Pol H., Kahn R. Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. Am J Psychiatry. 2008; 165(4): 490-6.
50. Rais M., van Haren NEM., Cahn W., Schank HG., Lepage C., Collins L., Evans AC., Hushoff Pol HE., Kahn RS. Cannabis use and progressive cortical thickness loss in areas rich in CB1 receptors during the first five years of schizophrenia. European Neuropsychopharmacology. 2010; 20(12): 855-65.
51. James A., Hough M., James S., Winmil L., Burge L., Nihawan S.,Matthews PM., Zarei M M.. Greater white and grey matter changes associated with early cannabis use in adolescent-onset schizophrenia (AOS). Schizophrenia Research. 2011; 128(1-3): 91-7.
52. Van Dijk D., Koeter MW., Hijman R., Kahn RS., van den Brink W.: Effect of cannabis use on the course of schizophrenia in male patients: A prospective cohort study. Schizophrenia Research. 2012; 137 (1-3): 50-57.
53. Zammit S., Moore TH., Lingford-Hughes A., Barnes TR., Jones PB., Burke M., Lewis G. Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br. J. Psychiatry. 2008; 193(5): 357-363.
54. Linszen DH., Dingemans PM., Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry. 1994;51(4):273-9.
55. Olfson M., Ascher-Svanum H., Faries DE., Marcus SC.: Predicting psychiatric hospital admission among adults with schizophrenia. Psychitric Serv. 2011, 62 (10) : 1138-1145.
56. Gorwood P.:Factors associated with hospitalisation of patients with schizophrenia in four European countries. European Psychiatry 2011; 26(4): 224-230.
57. Milev P., Ho BC., Arndt S., Andreasen NC.: Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first episode study with 7 year follow up. American Journal of Psychiatry. 2005; 162(3):495-506.
58. Green AI., Tohen MF., Hamer RM., Strakowski SM., Lieberman JA., Glick I., Clark WS.; HGDH Research Group. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res. 2004; 66(2-3): 125-35.
59. Stirling J., Lewis S., Hopkins R., White C. Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophr Res. 2005; 75(1): 135-7.
60. Arias Horcajadas F., Romero SS., Calo JJP. Relevance of drug use in clinical manifestations of schizophrenia. Actas Esp Psiquiatr. 2002; 30(2): 65-73.
61. Degenhardt L., Tennant C., Gilmour S., Schofield D., Nash L., Hall W., McKay D. The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study. Psychol Med. 2007; 37(7): 1-8.
62. Grech A., Van Os J., Jones PB., Lewis SW., Murray RM. Cannabis use and outcome of recent onset psychosis. Eur Psychiatry. 2005; 20(4): 349-53.
63. Foti DJ., Kotov R., Guey LT., Bromet EJ.: Cannabis use and the course of schizophrenia: 10-Year follow-up after first hospitalization. Am J Psychiatry. 2010; 167(8):987-993.
64. Caspari D. Cannabis and schizophrenia: results of a followup study. Eur Arch Psychiatry Clin Neurosci. 1999; 249(1): 45-9.
65. Dixon L., Haas G., Weiden P., Sweeney J., Frances A. Acute effects of drug abuse in schizophrenic patients: clinical observations and patients’ self-reports. Schizophr Bull. 1990;16(1):69-79.
66. Leeson VC., Harrison I., Ron MA., Barnes TR., Joy EM. The effect of cannabis use and cognitive reserve on age at onset and psychosis outcomes in first-episode schizophrenia. Schizophrenia Bull. 2012; 38(4): 837-880.
67. Loberg E., Hugdahl K. Cannabis use and cognition in schizophrenia. Front Hum Neurosci. 2009;3:1-8.
68. Jockers-Scherubl MC., Wolf T., Radzei N., Schlattmann P., Rentzsch J., Gómez-Carrillo de Castro A., Kuhl KP. Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls. Prog NeuroPsychopharmacol Biol Psychiatry. 2007; 31(5): 1054-1063.
69. Pencer A., Addington J., Addington D. Outcome of a first episode of psychosis in adolescence: a 2-year follow-up. Psychiatry Res. 2005; 133(1): 35-43.
70. Jablensky A., Sartorius N., Ernberg G. Schizophrenia: manifestations, incidence and course in different cultures, a World Health Organization 10-country study. Psychol Med Monogr Suppl. 1992; 20:1-97.
71. Weiden PJ., Kozma C., Grogg A., Locklear J: Partial compliance and risk of rehospitalization among California medicaid patients with schizophrenia. Psychiatric Services. 2004; 55 (8) :886-891.
72. Ayuso-Gutierrez JL., del Rio Vega JM.: Factors influencing relapse in the long-term course of schizophrenia. Schizophrenia Research. 1997; 28(2-3):199-206.
73. Valenstein M., Copeland LA., Blow FC., McCarthy JF., Zeber JE., Gillon L., Bingham CR., Stavenger T.: Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Medical Care 2002, 40:630-639.
74. Caseiro O., Perez-Iglesias R., Mata I., Martinez-Garcia O., Pelayo-Teran J., Tabares-Seisdedos R., Ortiz-Garcia de la Foz V., Vazquez-Barquero J., Crespo-Facorro B.: Predicting relapse after a first episode of non-affective psychosis: A three-year follow-up study. Journal of Psychiatric Research 2012, 46 (8) :1099-1105.
75. Weiden PJ., Zygmunt A.: The road back: working with the severely mentally ill. Medication noncompliance in schizophrenia: I. assessment. Journal of Practical Psychiatry and Behavioral Health. 1997 March:106-110.
76. Gilmer TP., Dolder CR., Lacro JP., Folsom DP., Lindamer L., Garcia P., Jeste DV DV.: Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. American Journal of Psychiatry. 2004; 161(4):692-699.
77. Coldham EL., Addington J., Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand. 2002;106(4):286-90.
78. Martinez-Arevalo MJ., Calcedo-Ordonez A., Varo-Prieto JR. Cannabis consumption as a prognostic factor in schizophrenia. Br J Psychiatry 1994; 164(5): 679-81.
79. Addington J., Addington D. Impact of an early psychosis program on substance use. Psychiatr Rehabil J. 2001; 25(1): 60-67.
80. Miller R., Caponi JM., Sevy S., Robinson D. The insightadherence - abstinence triad: An integrated treatment focus for cannabis-using first-episode schizophrenia patients. Bull Menninger Clin. 2005; 69(3): 220-236.
81. Perkins DO., Johnson JL., Hamer RM., Zipursky RB., Keefe RS., Centorrhino F., Green Al., Glick IB., Kahn RS., Sharma T., Tohen M., McEvoy JP., Weiden PJ., Lienerman JA.; HGDH Research Group. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic edpisode. Schizophr Res. 2006; 83(1):53-63.
82. Dekker N., Linszen DH., De Haan L. Reasons for cannabis use and effects of cannabis use as reported by patients with psychotic disorders. Psychopathology. 2009; 42(6): 350-360.
83. Semple DM., McIntosh AM., Lawrie SM. Cannabis as a risk factor for psychosis: systematic review. Journal of Psychopharmacology 2005;19(2): 187-194.
84. Smit F., Bolier F., Cuijpers P. Cannabis and risk of later schizophrenia: a review. Addiction. 2004;99(4):425-430.
85. Veen ND, Selten JP, Van Dit I, Feller WG, Hoek HW, Kahn RS. Cannabis use and age at onset of schizophrenia. American Journal Psychiatry. 2004;161(3):501-506.
86. Verdoux H., Gindre C., Sorbara F., Tournier M., Swendsen JD. Effects of cannabis and psychosis vulnerability in daily life: an experience sampling test study. Psychological Medicine 2003; 33(1): 23-32.
87. Jeste DV., McAdams LA., Palmer BW., Braff D., Jernigan TL., Paulsen JS., Stout JC., Symonds LL., Bailey A., Heaton RK.: Relationship of neuropsychological and MRI measures to age at onset of schizophrenia. Acta Psychiatr Scand. 1998; 98(2):156-164.
88. Tuulio-Henriksson A., Partonen T., Suvisaari J., Haukka J., Lonnqvist J.: Age at onset and cognitive functioning in schizophrenia. Br J Psychiatry. 2004; 185:215-219.
89. Lin CH., Chen MC., Chou LS., Lin CH., Chen CC., Lane HY. Time to rehospitalization in patients with major depression vs. those with schizophrenia or bipolar I disorder in a public psychiatric hospital. Psychiatry Research. 2010; 180(2-3): 74-79.
90. Lauronen E., Miettunen J., Veijola J., Karhu M., Jones PB, Isohanni M. Outcome and its predictors in schizophrenia within the Northern Finland 1966 Birth Cohort. European Psychiatry. 2007; 22(2):129-136
91. Malla A., Payne J. First-episode psychosis: psychopathology, quality of life, and functional outcome. Schizophrenia Bulletin. 2005; 31(3):650-671.
92. Rabinowitz J., Levine SZ., Hafner H. A population based elaboration of the role of age of onset on the course of schizophrenia. Schizophrenia Research. 2006; 88(1-3):96-101.
93. Hambrecht M., Häfner H: Substance abuse and the onset of schizophrenia. Biol Psychiatry. 1996; 40(11):1155-1163.
94. Van Mastrigt S., Addington J., Addington D: Substance misuse at presentation to an early psychosis program. Soc Psychiatry Psychiatr Epidemiol. 2004; 39:69-72.
95. Veen ND., Selten J-P., van der Tweel I., Feller WG., Hoek HW., Kahn RS.: Cannabis use and age at onset of schizophrenia. Am J Psychiatry 2004; 161(3):501-506.
96. Barnes TRE., Mutsatsa SH., Hutton SB., Watt HC., Joyce EM.: Comorbid substance use and age at onset of schizophrenia. Br J Psychiatry 2006; 188:237-242.
97. Compton MT., Kelley ME., Ramsay CE., PringleM., Goulding SM., Esterberg ML., Stewart T., Walker EF. Association of preonset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in first-episode patients. Am J Psychiatry. 2009; 166(11):1251-1257.
98. Sugranyes G., Flamarique I., Parellada E., Baeza I., Goti J., Fernandez-Egea E., Bernardo M. Cannabis use and age of diagnosis of schizophrenia. European Psychiatry. 2009; 24(5) 282-286.
